Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2a open label, single arm, multi-center clinical trial with GFH009 in combination with venetoclax and azacitidine in patients with relapsed/refractory (r/r) acute myeloid leukemia (AML)

Next Previous
Search
Trial Profile

Phase 2a open label, single arm, multi-center clinical trial with GFH009 in combination with venetoclax and azacitidine in patients with relapsed/refractory (r/r) acute myeloid leukemia (AML)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; Tambiciclib (Primary) ; Venetoclax (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 08 Jan 2025 According to a Sellas Life Sciences Group media release, company Opened enrollment in additional Phase 2 cohorts with the opening of two new cohorts - AML MRC with ASXL1 mutations and AML with myelodysplasia related changes other than ASXL1 mutations these new cohorts are also open for enrollment of certain pediatric patients.
    • 08 Jan 2025 According to a Sellas Life Sciences Group media release, company anticipates FDA feedback on regulatory path for r/r AML study expected in 1H 2025
    • 08 Jan 2025 According to a Sellas Life Sciences Group media release, anticipate full topline dataset from this trial in 1H 2025

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top